CFO
AUPH icon

CVA Family Office’s Aurinia Pharmaceuticals AUPH Stock Holding History

CVA Family Office’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.29K Hold
194
– – ﹤0.01% 1402
2026
Q1 		$2.88K Hold
194
– – ﹤0.01% 1422
2025
Q4 		$3.09K Sell
194
-90
-32% -$1.28K ﹤0.01% 936
2025
Q3 		$3.14K Buy
284
+90
+46% +$983 ﹤0.01% 945
2025
Q2 		$1.64K Hold
194
– – ﹤0.01% 1018
2025
Q1 		$1.56K Hold
194
– – ﹤0.01% 1038
2024
Q4 		$1.74K Hold
194
– – ﹤0.01% 1007
2024
Q3 		$1.42K Hold
194
– – ﹤0.01% 1026
2024
Q2 		$1.11K Buy
+194
New +$1.02K ﹤0.01% 1060
2024
Q1 		– Sell
-139
Closed -$1.25K – 1057
2023
Q4 		$1.25K Buy
+139
New +$1.15K ﹤0.01% 956

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CVA Family Office's AUPH Position: Q2 2026 in Review

CVA Family Office held its Aurinia Pharmaceuticals (AUPH) position steady in Q2 2026 at 194 shares worth $3.29K. The position accounts for ﹤0.01% of the portfolio, ranked #1402.

CVA Family Office first reported a position in AUPH in Q4 2023 and has held it in 10 quarters since. 282 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • CVA Family Office held 194 shares of Aurinia Pharmaceuticals worth $3.29K as of Q2 2026.
  • CVA Family Office left its Aurinia Pharmaceuticals share count unchanged in Q2 2026.
  • Aurinia Pharmaceuticals made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #1402 holding.
  • CVA Family Office first reported a position in Aurinia Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
  • 282 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.